News & SEC Filings

View the latest news and SEC filings

News

PDUFA Target Action Date for Ensifentrine of June 26, 2024  Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /…

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma…

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and…

LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call

SEC Filings

Date Form Filing Group

May 10, 2024

Quarterly report which provides a continuing view of a company’s financial position

10-Q

Quarterly Filings

May 10, 2024

Securities offered to employees pursuant to employee benefit plans

S-8

Registration Statements

May 9, 2024

Report of unscheduled material events or corporate event

8-K

Current Reports

May 9, 2024

Report of unscheduled material events or corporate event

8-K

Current Reports

May 3, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

May 3, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

May 3, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

April 30, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

April 30, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.